262 results
Page 2 of 14
8-K
EX-99.2
vbfn dj6k
13 Sep 22
Alnylam Announces Proposed Offering of $900 Million Convertible Senior Notes
4:05pm
8-K
EX-99.1
cgs6uhr4 zhm
28 Jul 22
Results of Operations and Financial Condition
8:10am
8-K
EX-99.1
tgbcluo2an9juue
14 Jun 22
Other Events
7:30am
8-K
EX-99.1
kxfztz7v074pt7zvow
28 Apr 22
Results of Operations and Financial Condition
8:10am
8-K
EX-99.1
qw2eyb
5 Apr 22
Alnylam Announces Retirement of Steven Paul, M.D. from Board of Directors
4:16pm
8-K
EX-99.1
hdjpe8v
4 Apr 22
Alnylam Announces 3-Month Extension of Review Period for New Drug Application for Vutrisiran
7:35am
8-K
EX-99.1
3jk407h3y0j
10 Feb 22
Results of Operations and Financial Condition
8:10am
8-K
EX-99.1
45u19pn wz
10 Jan 22
Alnylam Announces Preliminary* Fourth Quarter and Full Year 2021 Global Net Product Revenues and Provides Additional Updates
7:01am
8-K
EX-99.1
481top9ublizkqb
4 Jan 22
Alnylam Announces Promotion of Dr. Akshay Vaishnaw to President
4:16pm
8-K
EX-99.1
be9nz26j7qokx9l
28 Oct 21
Alnylam Pharmaceuticals Reports Third Quarter 2021 Financial Results and Highlights Recent Period Activity
8:11am
8-K
EX-99.2
8tv5jn
28 Oct 21
Alnylam Pharmaceuticals Reports Third Quarter 2021 Financial Results and Highlights Recent Period Activity
8:11am
8-K
36m4jvu
28 Oct 21
Alnylam Pharmaceuticals Reports Third Quarter 2021 Financial Results and Highlights Recent Period Activity
8:11am
8-K
of7sm
3 Aug 21
Alnylam Pharmaceuticals Reports Second Quarter 2021 Financial Results and Highlights
8:10am
8-K
EX-99.1
kvbtqhx0rq8hnm8jgmee
3 Aug 21
Alnylam Pharmaceuticals Reports Second Quarter 2021 Financial Results and Highlights
8:10am